Medium‐term follow up of active surveillance for early prostate cancer at a non‐academic institution

Abstract

ObjectivesTo report oncological outcomes of active surveillance (AS) at a single non‐academic institution adopting the standardised Prostate Cancer Research International Active Surveillance (PRIAS) protocol.Patients and MethodsCompeting risk analyses estimated the incidence of overall mortality, metastases, conversion to treatment, and grade reclassification. The incidence of reclassification and adverse pathological findings at radical prostatectomy were compared between patients fulfilling all PRIAS inclusion criteria vs those not fulfilling at least one.ResultsWe analysed 341 men with Grade Group 1 prostate cancer (PCa) followed on AS between 2010 and 2022. There were no PCa deaths, two patients developed distant metastases and were alive at the end of the study period. The 10‐year cumulative incidence of metastases was 1.9% (95% confidence interval [CI] 0.33–6.4%). A total of 111 men were reclassified, and 127 underwent definitive treatment. Men not fulfilling at least one PRIAS inclusion criteria (n = 43) had a higher incidence of reclassification (subdistribution hazards ratio 1.73, 95% CI 1.07–2.81; P = 0.03), but similar rates of adverse pathological findings at radical prostatectomy.ConclusionMetastases in men on AS at a non‐academic institution are as rare as those reported in established international cohorts. Men followed without stringent inclusion criteria should be counselled about the higher incidence of reclassification and reassured they can expect rates of adverse pathological findings comparable to those fulfilling all criteria. Therefore, AS should be proposed to all men with low‐grade PCa regardless of whether they are followed at academic institutions or smaller community hospitals.